Protagonist Therapeutics, Inc. (PTGX) News
Follow Protagonist Therapeutics, Inc. (PTGX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 24 public stories across 14 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Protagonist Therapeutics Q3 Revenue Surges on Takeda Payments
EQUITY | Nov 05, 2026, 09:46 PM UTC
M
Protagonist Therapeutics Reports Third-Quarter Revenue of $274.4 Million and Net Income of $220.0 Million
Third-quarter 2026 diluted earnings per share were $3.07, versus a loss of $0.62 per share a year earlier. Revenue was $4.7 million and net loss was $39.3 million in the prior-year quarter.
EQUITY | Nov 05, 2026, 09:39 PM UTC
M
Protagonist Therapeutics Reports $220.0M Q3 2026 Net Income
Protagonist reported Q3 2026 revenue of $274.4 million, versus $4.7 million in Q3 2025, and net income of $220.0 million, compared with a $39.3 million net loss. Cash, cash equivalents and marketable securities totaled $
EARNINGS | Nov 05, 2026, 09:09 PM UTC
M
Protagonist Reports Third-Quarter 2026 Results; FDA Approves MIMRYLO
Protagonist said MIMRYLO (rusfertide) was approved by the FDA for adults with polycythemia vera, triggering $275 million in payments. The company also plans to initiate a Phase 2b program for PN-881 in early Q1 2027.
EQUITY | Nov 05, 2026, 09:08 PM UTC
L
The Peptide Boom That Isn't About Your Muscles - Heard on the Street — WSJ
By David WainerPeptides are everywhere lately. Influencers inject them for muscle and recovery, and the Food and Drug Administration could soon allow these products to be sold by compounding pharmacies.While the marketin
NEWS | Sep 25, 2026, 09:30 AM UTC
L
PTGX: Strong drug approvals, innovative oral peptide pipeline, and strategic partnerships drive growth
Two drugs were approved this year, including MIMRYLO for PV, with strong commercial launches and robust pharma partnerships driving revenue and R&D. The pipeline focuses on oral peptide therapeutics targeting chronic dis
EQUITY | Sep 09, 2026, 04:53 PM UTC
L
PTGX cites approvals and partnerships; $300 million share repurchase
PTGX says two recently approved drugs with strong phase III data are driving revenue, enabling a $300 million share repurchase. The pipeline targets oral peptide therapeutics, with assets advancing in I&I, obesity and ra
EQUITY | Sep 09, 2026, 04:07 PM UTC
L
Protagonist Therapeutics to repurchase $300 million of shares
Protagonist Therapeutics (PTGX) announced a $300 million share repurchase program.
EQUITY | Sep 08, 2026, 08:05 PM UTC
H
DELAYED UPDATE — PTGX after FDA approval of MIMRYLO; analysts raise buy targets
Protagonist Therapeutics said the FDA approved MIMRYLO (rusfertide) in Aug 2026 for erythrocytosis in adult polycythemia vera. Phase 3 showed sustained hematocrit control; analysts including HC Wainwright, BMO, Barclays
REGULATION | Sep 07, 2026, 11:23 AM UTC
L
Protagonist Therapeutics CEO to participate in two September 2026 conferences
Protagonist Therapeutics said Dinesh V. Patel, President and Chief Executive Officer, will participate in two investment bank conferences in September 2026.
EQUITY | Sep 02, 2026, 11:05 AM UTC
L
PTGX - Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026
PTGX - Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026
EQUITY | Sep 02, 2026, 11:05 AM UTC
L
Protagonist Therapeutics price target raised to $180 by Barclays
Barclays raised its price target on Protagonist Therapeutics to $180.00 per share from $153.00, according to Benzinga (via TradingView News).
EQUITY | Sep 01, 2026, 06:55 PM UTC
L
BMO lifts Protagonist Therapeutics price target to $190
BMO Capital raised its Protagonist Therapeutics price target to $190.00 per share from $178.00 and maintained an Outperform rating, per Benzinga/TradingView.
EQUITY | Sep 01, 2026, 12:40 PM UTC
L
Protagonist Therapeutics maintained at Buy by Citigroup
Protagonist Therapeutics is maintained at a Buy rating by Citigroup.
EQUITY | Aug 31, 2026, 08:08 PM UTC
L
PTGX FDA approves MIMRYLO for PV
PTGX says the FDA approved MIMRYLO for PV, positioning it as erythrocytosis-specific therapy.
REGULATION | Aug 31, 2026, 04:09 PM UTC
L
PTGX maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. maintained its Buy rating on Protagonist Therapeutics (PTGX).
EQUITY | Aug 31, 2026, 02:53 PM UTC
M
PTGX FDA approves MIMRYLO for erythrocytosis in PV
PTGX says the FDA has approved MIMRYLO for erythrocytosis in PV, described as first-in-class with a broadly labeled therapy.
REGULATION | Aug 31, 2026, 02:40 PM UTC
M
PTGX gets FDA approval for MIMRYLO in polycythemia vera
PTGX said the FDA approved MIMRYLO for polycythemia vera.
REGULATION | Aug 31, 2026, 07:52 AM UTC
M
PTGX gets U.S. FDA approval for rusfertide in Polycythemia Vera
Protagonist Therapeutics said the U.S. FDA approved MIMRYLO (rusfertide) for Polycythemia Vera.
REGULATION | Aug 29, 2026, 12:30 AM UTC
M
US FDA approves Takeda and Protagonist rare blood cancer drug
US FDA approved Takeda and Protagonist's drug for a rare blood cancer.
REGULATION | Aug 28, 2026, 09:37 PM UTC
M
Protagonist Therapeutics grants inducement awards to employees
Protagonist Therapeutics (PTGX) reports it has granted inducement awards, with no further terms or totals provided in the feed.
EQUITY | Aug 18, 2026, 08:05 PM UTC
H
PTGX PT Raised to $173, $175 at Clear Street, Citi
PTGX price target raised
EQUITY | Aug 06, 2026, 12:04 PM UTC
L
PTGX - Protagonist Reports Second Quarter 2026 Financial Results and Provides Corporate Update
PTGX - Protagonist Reports Second Quarter 2026 Financial Results and Provides Corporate Update
EARNINGS | Aug 05, 2026, 08:05 PM UTC
L
PTGX PT raised from $137 to $165, maintains Market Outperform @ Citizens
PTGX PT raised from $137 to $165, maintains Market Outperform @ Citizens
EQUITY | Jul 17, 2026, 11:09 AM UTC